The SPEARHEAD-1 (NCT03132922) phase II trial of afamitresgene autoleucel (“afami-cel”), an HLA-A*02 restricted TCR targeting MAGE-4 in patients with synovial sarcoma or myxoid round cell liposarcoma, found an ORR of 37% and a duration of response of 28.1 months [167]. Here, HLA-A is linked to synovial sarcoma.